Thursday, Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes.

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Grinding pancreases for insulin at Eli Lilly and Company, early 1930s ... introduced standardized strengths and developed new long-acting insulins. Although not identical to human insulin, animal ...

Two years ago, Eli ... insulin market. Lilly has been under pressure in the US over its pricing for insulin products, and earlier this year launched a generic of its own Humalog brand of fast ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Drug company Eli Lilly announced it will cut the price of its insulin by 70 percent. How much will the drug cost and what does this mean for people with diabetes? Here's everything you need to ...